MRNA

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. (NASDAQ: MRNA) enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out

23 November 2025

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend

21 November 2025

Dividends · Financial Analysis · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity

20 November 2025

Biotechnology · Business News · Healthcare Industry · Investment · NASDAQ:MRNA · Pharmaceuticals

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down

8 October 2025

Biotechnology · Company News · Financial Analysis · Investing · NASDAQ:BNTX · NASDAQ:MRNA · NYSE:MRK · Stock Market